PLx Pharma (PLXP) Given Daily Media Impact Score of -0.03
Headlines about PLx Pharma (NASDAQ:PLXP) have trended somewhat negative recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. PLx Pharma earned a news sentiment score of -0.03 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.3926406940076 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of PLx Pharma (PLXP) traded up $0.11 during trading hours on Friday, hitting $6.90. 3,000 shares of the stock traded hands, compared to its average volume of 13,895. The company has a quick ratio of 8.88, a current ratio of 8.99 and a debt-to-equity ratio of 0.56. PLx Pharma has a one year low of $5.60 and a one year high of $22.00.
Several analysts have weighed in on PLXP shares. ValuEngine upgraded shares of PLx Pharma from a “strong sell” rating to a “sell” rating in a research note on Monday, December 4th. Zacks Investment Research cut shares of PLx Pharma from a “hold” rating to a “sell” rating in a research report on Thursday, November 16th.
COPYRIGHT VIOLATION WARNING: This article was first published by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/12/15/plx-pharma-plxp-given-daily-media-impact-score-of-0-03.html.
About PLx Pharma
PLx Pharma Inc, formerly Dipexium Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen.
Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.